AbbVie said a head-to-head study showed its drug Rinvoq was more effective in treating certain symptoms of moderate-to-severe atopic dermatitis than Sanofi (SNY) and Regeneron’s Dupixent in adults and adolescents. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment. (Seeking Alpha)
Early tests of H5N1 prevalence in milk have suggested the U.S. bird flu outbreak in cows is widespread. “The fact that you can go into a supermarket and 30% to 40% of those samples test positive, that suggests there’s more of the virus around than is currently being recognized,” said Richard Webby, an influenza virologist. (STAT News)
Regeneron Pharmaceuticals and Mammoth Biosciences announced plans to collaborate on researching, developing and commercializing gene editing therapies for multiple diseases. Mammoth’s CRISPR-based gene editing platform and Regeneron’s delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. (Reuters)
Former Dance Moms star Nia Sioux joined the latest iteration of the Ad Council’s Seize the Awkward mental health campaign. Capture the Convo, which marks Sioux’s directorial debut, features the actress and her friends sharing personal experiences and advice on how to have mental health conversations that can be both necessary and difficult. (MM+M)
How the Federal Trade Commission’s ban on noncompete clauses could have a big impact on healthcare. The FTC projected the rule could reduce health care costs by up to $194 billion in the next decade. (Axios)
Click here to view yesterday’s Five things for pharma marketers to know.
